While you may well be right about timing and the purpose of the update, I am not sure I agree that there is nothing new in the preso. While I think some commentary is needed, there are a number of incremental updates and additional numbers that were not in the half year results. There is a lot more information around the Sentia platform and direct ("in market") unit and strip sales and the a tightening of the indicative launch timeline for Fructose, Titratable Acidity and Acetic Acid.
On the Xpercia side we got more details on sales run rate and a forecast that they expect YoY revenue growth in the product line. We also are given a significant increase in the number of distributors and countries covered. We got an updated patient enrolment number for the Xpercia Prime FDA trial (308 of 360 needed)
We get our first glimpse of the Animal blood glucose unit and an indication first sales. We also get a management estimate of TAM for this market and that it is estimated that 112 strips per year will be need for each monitored animal. We get an incremental update on the COVID and Fertility platforms. We also get a better sense of the magnitude of the decrease in R&D costs next year and finally, although not new, a confirmation that management believe they have enough cash for operations and R&D.
UBI Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
